ReviewOncology letters2024

PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review).

Shuangcui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.